Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Prof. Amnon Peled is an associate professor and the Director of the Gene Therapy Institute at Hadassah Medical Center, Jerusalem. He directs a laboratory focused on the role of cytokines and chemokine receptors in hematopoietic stem cell biology, inflammation, and cancer. His laboratory supports the development of novel cell and molecular therapeutics for cancer and has been involved in the development of therapies currently in Phase II and III clinical studies. He is the founder of Biokine Therapeutics, AlonBio, and SakuraBio. Prof. Peled has authored over 100 publications and is listed as an inventor on over 200 patents related to therapeutic applications in stem cell biology, immunology, and cancer.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
Portfolio by sector
Health Tech & Life Sciences1
Q&A
- What is Amnon Peled's primary investment focus by sector?
- Amnon Peled has invested in the Health Tech & Life Sciences sector, with Biokine Therapeutics as a notable portfolio company.
- When did Amnon Peled make his most recent disclosed investment?
- Amnon Peled's most recent disclosed investment was in January 2007.
- Can you name a key company in Amnon Peled's portfolio?
- A key company in Amnon Peled's portfolio is Biokine Therapeutics, which develops anticancer and stem cell mobilization drugs.
- What is the typical investment range for Amnon Peled?
- Amnon Peled's investment range is typically $750K.
- What is the funding stage of Biokine Therapeutics, a company in Amnon Peled's portfolio?
- Biokine Therapeutics, a company in Amnon Peled's portfolio, is in the Mature funding stage and has raised $1.95M.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Radar intelligence
Patents
| EPO | 26 |
|---|